MIAMI — DNA repair capacity (DRC) measurements effectively identified individuals who were at high risk for non-melanoma skin cancer, and may be a useful method to evaluate the efficacy of preventive therapies, according to study results presented at the Third AACR Conference on the Science of Cancer Health Disparities.
"Our study showed that persons with low DRC have three times greater likelihood of having non-melanoma skin cancer as compared to those with high DRC," said Manuel Bayona, M.D., Ph.D., professor of the Public Health Program at the Ponce School of Medicine, Puerto Rico.
DRC is a complex cellular mechanism involving more than 200 proteins that is used to repair damage to DNA within cells. Bayona explained that DNA damage can be caused by exposure to solar ultraviolet light and other types of radiation, dietary factors and aging. DRC has been linked to several types of cancer development.
The researchers conducted a case-controlled study among participants in Puerto Rico to determine whether a reduced DRC was a risk factor for non-melanoma skin cancer.
After comparing DRC levels in 477 newly-diagnosed, non-melanoma skin cancer cases and 365 controls without cancer, they found that low DRC levels were strongly associated with non-melanoma skin cancer.
Bayona and colleagues also studied key risk factors and their possible association with DRC as predictors for non-melanoma skin cancer:
These findings in Puerto Rico are consistent with previous studies conducted elsewhere, according to the researchers. Additionally, participants who did not use sunblock, did not take aspirin and/or did not take multivitamin supplements regularly had increased odds of non-melanoma skin cancer.
"Doctors could use DRC levels to monitor how non-melanoma skin cancer risk decreases in individuals taking cancer preventive therapies," he said.
Follow the AACR on Twitter: @AACR #AACR
Follow the AACR on Facebook: http://www.facebook.com/aacr.org
The mission of the American Association for Cancer Research is to prevent and cure cancer. Founded in 1907, the AACR is the world's oldest and largest professional organization dedicated to advancing cancer research. The membership includes 32,000 basic, translational and clinical researchers; health care professionals; and cancer survivors and advocates in the United States and more than 90 other countries. The AACR marshals the full spectrum of expertise from the cancer community to accelerate progress in the prevention, diagnosis and treatment of cancer through high-quality scientific and educational programs. It funds innovative, meritorious research grants, research fellowships and career development awards. The AACR Annual Meeting attracts more than 18,000 participants who share the latest discoveries and developments in the field. Special Conferences throughout the year present novel data across a wide variety of topics in cancer research, treatment and patient care. The AACR publishes six major peer-reviewed journals: Cancer Research; Clinical Cancer Research; Molecular Cancer Therapeutics; Molecular Cancer Research; Cancer Epidemiology, Biomarkers & Prevention; and Cancer Prevention Research. The AACR also publishes CR, a magazine for cancer survivors and their families, patient advocates, physicians and scientists, providing a forum for sharing essential, evidence-based information and perspectives on progress in cancer research, survivorship and advocacy.
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.